Armin Ehninger

Armin Ehninger's most recent work experience is as the Chief Scientific Officer at AvenCell, where they lead the development of a switchable, universal CAR-T platform in combination with Intellia's proprietary CRISPR-based allogeneic platform. This innovative approach aims to address the weaknesses and safety issues associated with existing cell therapy treatments. Prior to their role at AvenCell, Armin served as the Chief Scientific Officer at GEMoaB GmbH from 2013 to 2021. Armin also has experience as a post-doctoral fellow at the HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine, as well as a graduate student at the DKFZ German Cancer Research Center and the ISREC Swiss Institute of Cancer Research. Armin completed their diploma thesis at TU Dresden, and has interned at Living Cell Technologies Ltd. and conducted a student research project at Auckland Cancer Society Research Centre, University of Auckland.

Armin Ehninger pursued their education from 2000 to 2006 at the University of Stuttgart. During this period, they completed their diploma in biology, also known as a "Diplom Biologe t.o.," as well as earned a Master of Science degree in biology. Armin'sfield of study specifically focused on technical biology, delving into the intersection of biology and technology.